Celiac disease is a chronic condition that requires a structured, lifelong management approach. This page summarises the principal treatment strategy and the clinical goals it aims to achieve. The complete, structured protocol is available via the link below.
The primary aims of treatment are rapid symptom relief, seroconversion from positive to negative celiac serology, and progressive intestinal mucosal healing. Most patients see meaningful symptom improvement within the first weeks of adherent therapy, with full mucosal recovery achievable over a period of months to years depending on the individual.
First-line management centres on strict, lifelong adherence to a gluten-free diet — recognised as the only effective therapeutic intervention for celiac disease. The protocol includes specific guidance on certain grain-derived products and their tolerability monitoring, as well as evidence-based preventive vaccination recommendations for eligible adult patients.
DOI: 10.14309/ajg.0000000000002075
Current treatment of CD requires strict adherence to a GFD and lifelong medical follow-up.
A GFD is the only effective therapy for CD.
We recommend consumption of gluten-free oats in the diet of those with CD.
We suggest vaccination to prevent pneumococcal disease in patients with CD.
It is expected that symptoms improve within days of strict adherence to a GFD (e.g., diarrhea improved in most patients [80%] within 60 days).
Mucosal healing was observed in 95% children within 2 years of starting a GFD.
In a US study, the median time from the onset of GFD to achieve mucosal healing in adults was 3 years.
View source ↗